Collaborations, Facility Expansions, and Regulatory Approvals Open Opportunities for Revenue Growth - Research Report on Johnson & Johnson, Zoetis, CVS Caremark, Omnicare, and Novartis Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, July 12, 2013 NEW YORK, July 12, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Zoetis Inc. (NYSE: ZTS), CVS Caremark Corporation (NYSE: CVS), Omnicare, Inc. (NYSE: OCR), and Novartis AG (ADR) (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Johnson & Johnson Research Report On July 2, 2013, Mentor Worldwide LC (Mentor), a Johnson & Johnson (Johnson & Johnson) company, announced that it has entered into a 5 year Collaboration Agreement (agreement) with the Medicis division (Medicis) of Valeant Pharmaceuticals (Valeant). Under the terms of the agreement, the partnership will form physical loyalty program called the M^[^2^]VP Program (Medicis-Mentor Valued Partner Program), which will offer the MENTOR line of breast implant products for the aesthetics (non-reimbursed) market, and Medicis non-reimbursed facial aesthetic products, including neurotoxin, fillers, and skin care. Mentor said that the program rewards the use of various products across the Mentor and Medicis portfolios, allowing participants to earn points which establish status within the program and can be redeemed for product purchases. David J. Wilson, Worldwide President of Mentor said, "We believe the creation of a combined loyalty program allows both organizations to deliver more value and choice to plastic surgeons operating in an increasingly competitive market." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0ba3_JNJ] -- Zoetis Inc. Research Report On July 2, 2013, Zoetis Inc. (Zoetis) announced its plans to expand its manufacturing facility in Lincoln, Nebraska, to ensure consistent supply of high-quality, reliable medicines for veterinarians, livestock producers, and animals under their care. The Company intends to add in a 19,000 square-foot, three-story to the existing production facility by 2014, so as to accommodate the transfer of products from a third-party manufacturer to Lincoln. With the upcoming expansion, Zoetis aims to affirm its longstanding commitment to being a world-class manufacturer of animal health products. Zoetis currently employs more than 500 people at its Lincoln plant, and it expects the expansion to create as many as 30 new positions at peak production time. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/7e28_ZTS] -- CVS Caremark Corporation Research Report On July 1, 2013, CVS/pharmacy, the retail division of CVS Caremark Corporation (CVS Caremark), announced the launch of its new Drug Interaction Checker as a part of its top-rated CVS Mobile app. According to CVS/pharmacy, the app allows customers to check for potential drug interactions by comparing over-the-counter (OTC) products with their prescriptions and other OTCs on their smartphones. The users need to enter the name of the product or active ingredients and the new app compares the available product details against the OTCs or prescription medications that are entered or imported through the patient's secure pharmacy history. Later, it identifies the possible interactions based on a comprehensive and continually updated database of drug information to alert users of any potential issues. CVS Caremark said that the Drug Interaction Checker adds to the already existing pack of health resources offered on the CVS Mobile app, and is available as a free download from Apple's App Store or through Google Play. Current users can update their existing app to instantly receive the new feature. The Full Research Report on CVS Caremark Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/f831_CVS] -- Omnicare, Inc. Research Report On July 5, 2013, Omnicare, Inc. (Omnicare) announced the appointment of James (Jim) Carlson to its Board of Directors, effective July 1, 2013. Mr. Carlson served as CEO of Amerigroup Corporation (Amerigroup) from 2007 to 2012, and became the chairman of Amerigroup's Board of Directors in 2008. Omnicare stated that under Mr. Carlson's leadership, Amerigroup more than doubled the number of state Medicaid programs it served, as well as recorded more than four-fold growth in its revenues. With Mr. Carlson's appointment, the Company's Board has now expanded to ten directors, nine of whom are independent. The Full Research Report on Omnicare, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e195_OCR] -- Novartis AG (ADR) Research Report On July 5, 2013, Novartis AG (ADR) (Novartis) announced that the European Commission has granted the Company a new indication for Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). According to Novartis, this makes Lucentis the first anti-VEGF (vascular endothelial cell growth factor) therapy licensed for four indications in the European Union. Novartis said that RADIANCE, the Company sponsored clinical trials in patients with myopic CNV, showed that Lucentis provides rapid and superior improvement in visual acuity compared with the current standard of care, Visudyne (verteporfin). The trial also revealed that in patients with myopic CNV, there is an average 14-letter visual acuity gain in the first year with a median of 2 injections, and over 60% of patients in RADIANCE did not need further injections after six months. The Full Research Report on Novartis AG (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/956c_NVS] -- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com, Phone #: +1-310-496-8071 (North America)
Collaborations, Facility Expansions, and Regulatory Approvals Open Opportunities for Revenue Growth - Research Report on Johnson
Press spacebar to pause and continue. Press esc to stop.